Biomedical Engineering Reference
In-Depth Information
5. World Health Organization: The Global Burden of Disease: 2004 Update. WHO Press,
Geneva (2008)
6. Holaday, J.W., Berkowitz, B.A.: Antiangiogenic drugs: insights into drug development from
endostatin, avastin and thalidomide. Mol. Interventions 9(4), 157-166 (2009)
7. Senger, D.R., et al.: Tumor cells secrete a vascular permeability factor that promotes
accumulation of ascites fluid. Science 219(4587), 983-985 (1983)
8. Baeriswyl, V., Christofori, G.: The angiogenic switch in carcinogenesis. Semin. Cancer Biol.
19(5), 329-337 (2009)
9. Pugh, C.W., Ratcliffe, P.J.: Regulation of angiogenesis by hypoxia: role of the HIF system.
Nat. Med. 9(6), 677-684 (2003)
10. Mitchell, D.C., Bryan, B.A.: Anti-angiogenic therapy: adapting strategies to overcome
resistant tumors. J. Cell. Biochem. 111(3), 543-553 (2010)
11. Abdelrahim, M., et al.: Angiogenesis: an update and potential drug approaches. Int. J. Oncol.
36(1), 5-18 (2010)
12. Carmeliet, P., et al.: Abnormal blood vessel development and lethality in embryos lacking a
single VEGF allele. Nature 380(6573), 435-439 (1996)
13. Prior, B.M., Yang, H.T., Terjung, R.L.: What makes vessels grow with exercise training? J.
Appl. Physiol. 97(3), 1119-1128 (2004)
14. Ferrara, N., Gerber, H.P., LeCouter, J.: The biology of VEGF and its receptors. Nat. Med.
9(6), 669-676 (2003)
15. Friesel, R.E., Maciag, T.: Molecular mechanisms of angiogenesis: fibroblast growth factor
signal transduction. FASEB J 9(10), 919-925 (1995)
16. Beohar, N., et al.: Rebuilding the damaged heart: the potential of cytokines and growth
factors in the treatment of ischemic heart disease. J. Am. Coll. Cardiol. 56(16), 1287-1297
(2010)
17. Kapur, N.K., Rade, J.J.: Fibroblast growth factor 4 gene therapy for chronic ischemic heart
disease. Trends Cardiovasc. Med. 18(4), 133-141 (2008)
18. Frontini, M., et al.: Fibroblast growth factor 9 delivery during angiogenesis produces durable,
vasoresponsive microvessels wrapped by smooth muscle cells. Nat. Biotechnol. 29(5),
421-427 (2011)
19. Liekens, S., De Clercq, E., Neyts, J.: Angiogenesis: regulators and clinical applications.
Biochem. Pharmacol. 61(3), 253-270 (2001)
20. Gupta, K., Zhang, J.: Angiogenesis: a curse or cure? Postgrad. Med. J. 81(954), 236-242
(2005)
21. Klagsbrun, M., Moses, M.A.: Molecular angiogenesis. Chem. Biol. 6(8), R217-R224 (1999)
22. O'Reilly,
M.S.,
et
al.:
Angiostatin:
a
novel
angiogenesis
inhibitor
that
mediates
the
suppression of metastases by a Lewis lung carcinoma. Cell 79(2), 315-328 (1994)
23. O'Reilly, M.S., et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.
Cell 88(2), 277-285 (1997)
24. Albini, A., et al.: Angiostatin anti-angiogenesis requires IL-12: the innate immune system as
a key target. J. Transl. Med. 7, 5 (2009)
25. Lachgar, S., et al.: Inhibitory effects of retinoids on vascular endothelial growth factor
production by cultured human skin keratinocytes. Dermatology 199(Suppl 1), 25-27 (1999)
26. Folkman, J., Ingber, D.E.: Angiostatic steroids: method of discovery and mechanism of
action. Ann. Surg. 206(3), 374-383 (1987)
27. Mathers, C.D., Loncar, D.: Projections of global mortality and burden of disease from 2002 to
2030. PLoS Med 3(11), e442 (2006)
28. McMurray, J.J., Stewart, S.: Heart failure: epidemiology, aetiology, and prognosis of heart
failure. Heart 83(5), 596-602 (2000)
29. van der Laan, A.M.: Targeting angiogenesis to restore the microcirculation after reperfused
MI. Nat. Rev. Cardiol. 6(8), 515-523 (2009)
30. Christoforou, N., Gearhart, J.D.: Stem cells and their potential in cell-based cardiac therapies.
Prog. Cardiovasc. Dis. 49(6), 396-413 (2007)
Search WWH ::
Custom Search